Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RiMO-301 |
| Trade Name | |
| Synonyms | RiMO301|RiMO 301 |
| Drug Descriptions |
RiMO-301 is a nanoparticle-based metal-organic framework that may enhance radiosensivity and activity of immunotherapy (PMID: 32607433, J Clin Oncol 2023 41:16_suppl, 2527). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C148280 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Nivolumab + RiMO-301 | Nivolumab RiMO-301 | 0 | 1 |
| Pembrolizumab + Radiotherapy + RiMO-301 | Pembrolizumab Radiotherapy RiMO-301 | 0 | 0 |
| Pembrolizumab + RiMO-301 | Pembrolizumab RiMO-301 | 0 | 1 |
| Radiotherapy + RiMO-301 | Radiotherapy RiMO-301 | 0 | 0 |
| RiMO-301 | RiMO-301 | 0 | 1 |